Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00118417

Therapies for Treatment-Resistant Panic Disorder Symptoms

Treatment Refractory Panic Disorder

Sponsor: Massachusetts General Hospital

Interventions Clonazepam Cognitive behavioral therapy Sertraline

Updated 6 times since 2017 Last updated: Jun 5, 2014 Started: Mar 31, 1999 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Panic Disorder, this trial is completed. The trial is conducted by Massachusetts General Hospital and has accumulated 6 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Mar 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital
National Institute of Mental Health (NIMH)

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States